Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
Abstract Insulin aspart (IAsp) is one of the main therapies used to control blood glucose after a meal. This study aimed to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of 2 rapid-acting IAsp products: a new IAsp biosimilar (RD10046) and NovoRapid. In a single-center, randomized, sing...
Saved in:
Main Authors: | Hui Liu, Hongling Yu, Lisi Sun, Jingtao Qiao, Sainan Wai, Shuang Li, Jiaqi Li, Huiwen Tan, Yerong Yu |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/b9a0825201e5476e81ccc868c6a633d2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Author Correction: Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
by: Hui Liu, et al.
Published: (2021) -
Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects
by: Masanari Shiramoto, et al.
Published: (2021) -
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
by: Irina A. Proskurina, et al.
Published: (2016) -
Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
by: Hanne Haahr, et al.
Published: (2020) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014)